Search - tctmd.com

Displaying 1 - 20 of 104

Sort: Relevancy | Date

News Daily News

February 2026 Dispatch for the CV Team

L.A. McKeown

February 18, 2026

News Daily News

Oral GLP-1s Provide Benefit in HF Patients: SOUL Subanalysis

L.A. McKeown

February 06, 2026

News Daily News

JACC Debuts Data Digest on CV Health in the United States

Caitlin E. Cox

January 12, 2026

News Opinion CV Team Dispatch

December 2025 Dispatch for the CV Team

L.A. McKeown

December 23, 2025

News Daily News

Remission From Prediabetes Halves CV Risk: Registry Data

Yael L. Maxwell

December 19, 2025

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

News Daily News

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

L.A. McKeown

July 24, 2025

News Daily News

Some Ups, Some Downs in Proposed CMS Reimbursement for 2026, Cardiologists Say

L.A. McKeown

July 22, 2025

News Conference News HRS 2025

GLP-1 Drugs May Have Role in Secondary Prevention of AF

Todd Neale

April 28, 2025

News Opinion CV Team Dispatch

April 2025 Dispatch for the CV Team

L.A. McKeown

April 18, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

News Daily News

CVD Hospitalization in Older Adults Higher in US Than in Denmark

Michael O'Riordan

February 07, 2025

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

News Daily News

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

Yael L. Maxwell

August 15, 2024

News Daily News

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

L.A. McKeown

August 05, 2024

News Conference News ACC 2024

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

L.A. McKeown

April 06, 2024

News Daily News

Even After Multivessel or LM PCI, Routine Stress Testing Adds Nothing

Yael L. Maxwell

March 01, 2024

News Opinion CV Team Dispatch

February 2024 Dispatch for the CV Team

L.A. McKeown

February 01, 2024

Advertisement

February 2026 Dispatch for the CV Team

Oral GLP-1s Provide Benefit in HF Patients: SOUL Subanalysis

JACC Debuts Data Digest on CV Health in the United States

December 2025 Dispatch for the CV Team

Remission From Prediabetes Halves CV Risk: Registry Data

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

Some Ups, Some Downs in Proposed CMS Reimbursement for 2026, Cardiologists Say

GLP-1 Drugs May Have Role in Secondary Prevention of AF

April 2025 Dispatch for the CV Team

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

CVD Hospitalization in Older Adults Higher in US Than in Denmark

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

Even After Multivessel or LM PCI, Routine Stress Testing Adds Nothing

February 2024 Dispatch for the CV Team

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content